Comparative study of proguanil and sulphadoxine– pyrimethamine in the prevention of malaria in pregnancy by Lasisi, Adewale Jamiu et al.
73© 2018 Tropical Journal of Obstetrics and Gynaecology | Published by Wolters Kluwer - Medknow
AbstRACt
background: Intermittent preventive treatment of malaria in pregnancy with sulphadoxine–pyrimethamine (SP) is 
recommended for prevention of malaria in pregnancy. However, chemoprophylaxis with proguanil (PG) is being used in 
pregnancy for preventing malaria in selected cases. 
Objective: To compare the efficacy of daily PG and intermittent monthly SP in preventing malaria and its complications 
during pregnancy. 
Patients and Methods: This was a prospective comparative study conducted among 270 consenting pregnant women 
with parity ≤2 at gestational age of 18–24 weeks. Participants were enrolled and randomized to PG or SP group following 
a baseline hemoglobin estimation and blood film negative for malaria parasite. At 36 weeks of gestation, maternal blood 
sample was checked for hemoglobin concentration and malaria parasitaemia, and the infant birth weight was assessed 
at delivery.
statistical Analysis: Appropriate univariate, and bivariate analysis employed and level of significance set at P < 0.05.
Results: One hundred and thirty‑five participants in each group (246) completed the study. Ten (8.5%) had malaria 
parasitaemia in the PG group at 36 weeks compared to 15 (11.7%) in the SP group (P = 0.40); 5 (4.3%) in the PG compared 
with 6 in SP group (4.7%) had anemia (Hb <10 g/dl) at 36 weeks (P = 0.86). In addition, 6 (5.1%) participants in the PG 
group developed clinical malaria compared to 3 (2.3%) in the SP group (P = 0.25). The mean infant birth weight in the PG 
and SP groups were 3.05 kg and 3.00 kg, respectively (P = 0.24). 
Conclusion: PG and SP were comparable in efficacy and outcome for malaria prevention during pregnancy. IPT‑SP is 
recommended for prevention of malaria in pregnancy. However, PG is beneficial in selected patients with known adverse 
reactions to sulphonamide.
Key words: Intermittent preventive treatment; malaria infection; malaria prevention; malaria in pregnancy; proguanil; 
sulphadoxine–pyrimethamine.
Introduction
Malaria in pregnancy, a major public health problem, 
has continued to result in high morbidity and mortality 
in Sub-Saharan Africa, South-east Asia, and Papua New 
Guinea.[1-3] It is associated with deleterious effects to the 
mother, fetus, and the newborn.[4,5]
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Original  Article
There are at least 300 million acute cases of malaria each 
year globally resulting in more than a million deaths. 
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About 90% of these deaths occur in Africa, mostly in 
young children and pregnant women.[2-5] According to the 
World malaria report, Nigeria accounts for a quarter of all 
malaria cases in the 45 malaria endemic countries in Africa, 
highlighting the challenge of malaria in Nigeria.[6,7] Every 
year, at least 30 million pregnancies occur among women in 
malaria-endemic areas of Africa, most of who reside in areas 
of stable malaria transmission.[4,5] The Sub-Saharan Africa 
region represents areas of high and moderate (stable) malaria 
transmission.[3-5] Women who have lived in endemic areas 
without protection from malaria will have acquired partial 
immunity from recurrent parasitaemia by the time they are 
old enough to become pregnant, just like any other adult 
indigenous to endemic areas.[5,8-11]
Most malaria infections are caused by Plasmodium spp.; 
P. falciparum falciparum; causing the most severe and 
life-threatening form of the disease.[4] There are other 
identified species causing human malaria, namely, P. vivax, 
P. ovale, P malariae, and P knowlesi.[4,12] In Nigeria, 98% of all 
cases of malaria are caused by P. falciparum.[1,5,7]
Malaria in pregnancy is an obstetric, social, and medical 
problem; and pregnant women constitute the main adult 
high-risk group.[10] Malaria and pregnancy are mutually 
aggravating conditions.[4,10] The physiological changes during 
pregnancy and pathological changes due to malaria both 
have synergistic effects on the course of the pregnancy 
and disease.[10] The frequency and severity of malaria are 
greater in the pregnant than the nonpregnant state, and the 
complications of malaria are more likely to result in mortality 
in pregnant than that in nonpregnant women.[5,10] Nonimmune 
primigravidae are most affected compared to multigravidae 
who have developed immunity from previous episodes of 
malaria parasitaemia in pregnancy.[5,11,12]
The pathophysiology of malaria in pregnancy is due to the 
altered immunity and presence of the placenta in pregnancy. 
Multigravidae are able to develop strain-independent 
antibodies against chondroitin sulphate A (CSA)-specific 
parasite antigen. These are antiadhesive antibodies and 
prevent P. falciparum sequestration in the placenta; these 
antibodies are lacking in the primigravidae, resulting in 
susceptibility to malaria infestation.[10,12]
Most immune pregnant women are asymptomatic in the 
presence of parasitaemia. The complications of malaria 
include anaemia, hypoglycemia, cerebral malaria, and 
pulmonary edema; and maternal mortality can occur from 
severe malaria.[3,10] Others include miscarriage or preterm 
labor, delivery of low birth weight infants, prematurity, 
intrauterine growth restriction (IUGR), and intrauterine fetal 
death (IUFD).[1,9-12] All these account for relative increase in 
maternal and perinatal morbidity and mortality associated 
with malaria in pregnancy.[11]
Previous studies have shown that regular chemoprophylaxis 
prevents malaria attack and its associated complications. 
More recently, intermittent preventive treatment for 
malaria using sulphadoxine–pyrimethamine (SP) has 
been shown to be cost-effective and efficacious in 
reducing malaria infection and complications of malaria 
in pregnancy.[1,5,13-15] Some studies have shown that use 
of regular chemoprophylaxis against malaria in addition 
to the use of iron and folate supplementation as part 
of routine antenatal care remains a life-saving regimen 
through the prevention of acute malaria and its associated 
complications, especially anemia.[1,5,10]
Some studies, including randomized controlled trials 
and prospective studies conducted in Kenya, Malawi, and 
Mozambique,[5,16-18] have demonstrated the efficacy, safety, 
and cost-effectiveness of SP in preventing maternal anemia 
and low birth weight arising from malaria in pregnancy. 
However, SP is not recommended in the first trimester of 
pregnancy because of the risk of congenital malformations 
and neural tube defects. It is associated with adverse 
reactions, especially in individuals allergic to sulphonamide, 
and there is a rise in resistance to SP.[14,19-21]
Proguanil (PG) has been in use for prophylaxis against 
malaria; it is safe, well-tolerated, and effective in malaria 
prevention.[14,22] Studies in Nigeria have also shown its efficacy 
when used alone or in combination with chloroquine in 
reducing the prevalence of falciparum parasitaemia.[22,23] 
One of such studies comparing PG only to chloroquine–
proguanil for malaria chemoprophylaxis found a reduction 
of malaria parasitaemia at recruitment from 32% and 35% 
in the respective groups to about 2% in both groups during 
follow-up at 28 weeks and 36 weeks. It also reduced severe 
anemia from 18% to 3% and increased mean birth weight by 
approximately 132 g.[22,23]
It is necessary to seek alternate regimens of proven efficacy 
for malaria prevention during pregnancy. The aim of this study 
is to compare the efficacy of PG in the prevention of malaria 
in pregnancy with SP as an alternative to SP for patients with 
allergy or adverse reactions to sulphonamides.
Patients and Methods
Ethics: Ethical approval was obtained by the State research 
ethics review committee.
Lasisi, et al.: Proguanil VS sulphadoxine-pyrimethamine for prevention of malaria in pregnancy
75Tropical Journal of Obstetrics and Gynaecology / Volume 35 / Issue 1 / January‑April 2018
Study design: This was a prospective study conducted at 
the obstetric unit of a secondary health care facility in 
Southwestern Nigeria. The study was conducted following 
ethical approval by the State research ethics review 
committee. The study was a comparative study conducted 
over a 7-month period among pregnant women in their 
first or second pregnancies receiving antenatal care in the 
hospital.
The sample size was calculated using a parasitologic failure 
rate of 6.6% among women using IPT-SP for prevention of 
malaria in pregnancy found by a previous study in Ile-Ife,[5] 
a power of 80%, confidence interval of 95%, and an attrition 
rate of 10%; a sample size of 270 was obtained. Two hundred 
and seventy (270) participants were enrolled into the study 
with 135 in each group.
The inclusion criteria were pregnant women with parity not 
more than Para 2, singleton pregnancy who have not had 
IPT-p, gestational age 18–24 weeks, no clinical or laboratory 
evidence of malaria, Hb A genotype, and no known adverse 
reaction to sulphadoxine, pyrimethamine or PG.
The exclusion criteria were evidence of malaria infection at 
recruitment, moderate-to-severe anemia, sickle cell disease, 
multiple pregnancies, adverse reactions to sulphadoxine, 
pyrimethamine, or PG, and HIV positive patients.
Eligible participants were enrolled after counselling and 
obtaining informed consent. Enrolment was done by the 
investigator and research assistant trained for the study. 
A data collection form was filled for each participant 
and subsequently randomized using a simple random 
technique.
Allocation into groups
Paper ballots were generated for the two groups – group A, the 
intervention group (PG) and group B, the control group (SP); 
paper ballots were generated by an assistant blinded to 
the groups and sealed ballots were placed in a concealed 
envelope. These were administered by the trained research 
assistant who was also blinded and participants were asked to 
pick a single ballot from the concealed envelope and allocated 
appropriately. Blinding was thus limited to group allocation as 
the drugs were of different dosing regimen; thus, participants 
were not blinded. Serial numbers were allocated and recorded 
as well as participants’ hospital number. A structured 
questionnaire was administered to obtain sociodemographic 
and clinical information about the participant.
Participants in group A received oral PG 200 mg daily 
(Reludrine, Osaka pharmaceuticals India); they were 
counseled regarding the need for strict compliance. 
Compliance was ensured by double checking sachets of drugs 
used during subsequent antenatal clinic visits as described 
below. They were advised and encouraged to take the drug as 
part of routine antenatal hematinic to encourage compliance.
Participants in group B received two doses of oral SP 
(Malareich, Meidreich Ltd India) as direct observed therapy 
at clinic visits. Each dose comprised three tablets of SP 
each containing 500 mg of sulphadoxine and 25 mg of 
pyrimethamine. The first dose was administered at entry point 
(18–24 weeks gestation) and the second dose at least 4 weeks 
apart ensuring both doses are in the second and early third 
trimester (26–32 weeks). Routine hematinic (Ferrotone, Mega 
life pharmaceuticals Nigeria) were provided for all participants.
Maternal blood sample was taken for hemoglobin estimation 
at enrolment and at 36 weeks. Baseline thick and thin blood 
films for malaria parasite and species determination was 
carried out (using standard Giemsa staining) at enrolment 
to exclude asymptomatic malaria parasitaemia and 
repeated at 36 weeks. This was also done for participants 
with symptoms of malaria to confirm diagnosis prior to 
treatment. Participants with confirmed malaria parasitaemia 
were treated with arthemeter-lumefantrine combination 
therapy (Lonart, Bliss Gvspharmaceuticals India).
The participants continued routine antenatal care and 
patient’s compliance ascertained verbally and cross checked 
with a pill count by the research assistant; the research 
assistant thereafter dispensed more drugs. Noncompliant 
participants were advised to opt out of the study.
At 36 weeks gestation, participants had repeat blood film 
for malaria parasitaemia and hemoglobin concentration. 
At delivery, the infant birth weight was measured within 
30 min of delivery using an analogue infant weighing scale. 
Participants who did not deliver at the study site were 
considered lost to follow-up.
Data analysis
All data collected was collated, entered and analyzed using 
STATA version 11 statistical package. Frequency tables 
were drawn and proportions generated. Association was 
determined for categorical variables using Chi-square (χ2) 
test and student’s t-test for continuous variables. The level 
of statistical significance was set at P < 0.05.
Results
Two hundred and seventy (270) women participated 
in the study. A total of 246 participants completed the 
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study, with 118 participants (87.41%) in the PG group and 
128 participants (94.81%) in the SP group. Twenty-four 
participants (8.9%) were lost to follow-up and poor 
compliance; 17 (12.59%) and 7 (5.19%) in the PG and SP 
groups, respectively.
The sociodemographic characteristics of participants are 
shown in Table 1. The mean age was significantly higher in the 
PG group, 27.6 ± 3.62 years compared to 26.3 ± 3.32 years 
in SP group (P = 0.01). There was no statistically significant 
difference in gestational age at enrolment, parity, educational 
status, and occupation of the participants.
All participants had negative blood film for malaria parasite 
at enrolment. The incidence of clinical malaria in both study 
groups is shown in Table 2. Six participants (5.1%) in the PG 
group and 3 participants (2.3%) in the SP group had malaria 
infection (P = 0.25). Only two participants (1.7%) in the PG 
group and none in the SP group had repeat malaria episode 
during the study period (P = 0.23). Ten participants (8.5%) 
in the PG group compared to 15 (11.7%) in the SP group had 
positive malaria parasitaemia at 36 weeks (P = 0.40).
The mean hemoglobin concentrations at recruitment and 
at 36 weeks gestation are shown in Table 3; these were 
10.53 g/dl and 10.63 g/dl in the PG and SP groups, respectively, 
at recruitment (P = 0.40), while at 36 weeks it was 
11.17 g/dl and 11.24 g/dl respectively (P = 0.78). Twenty eight 
participants (23.7%) had anaemia (Hb< 10 g/dl) at recruitment 
in the PG group compared to 22 participants (17.2%) in the 
SP group (P = 0.20). At 36 weeks, 5 participants (4.3%) in 
the PG group and 6 participants (4.7%) in the SP group had 
Hb <10 g/dl, P = 0.86 [Table 3].
The mean infant birth weight at delivery was 3.05 kg in the PG 
group and comparable to 3.00 kg in the SP group (P = 0.24).
Discussion
In this study, only 8.5% of participants in the PG group had 
peripheral malaria parasitaemia at 36 weeks of gestation 
in contrast to 11.7% of the participants in the SP group. 
This difference was not statistically significant or clinically 
significant.
The incidence of malaria parasitaemia in the PG group 
was higher than that reported by a previous study by 
Harrison et al. in Zaria,[24] which found an incidence of 2%. The 
participants in the study were recruited at about 24 weeks 
of gestation and were followed up till 36 weeks of gestation; 
peripheral malaria parasitaemia was checked at 28 weeks 
and at 36 weeks. This difference may be due to the variation 
in the study population and climatic variation between the 
southwest and Northern parts of Nigeria. The longer period 
of follow-up in this study may also be contributory to the 
observed difference. The incidence of malaria in this study 
is also lower than the incidence of 9.3% in the PG group 
in another study comparing PG with chloroquine among 
pregnant women.[25]
The incidence of peripheral malaria parasitaemia at 36 weeks 
gestation in the SP group of this study (11.7%) was higher 
compared to incidence of 6.6–10.4%, 5.3%, and 6% reported 
in similar studies in Nigeria, Kenya, and Mozambique, 
respectively;[5,15,16,18] however, lower than 36% reported fro 
Malawi.[26]







Mean age (years) 27.6±3.62 26.3±3.32 0.01
GA at booking (mean) 21.8±2.0 21.7±2.02 0.66
Marital status
Married 115 (97.5) 118 (92.2) 0.07
Not married 3 (2.5) 10 (7.8)
Parity
0 42 (35.6) 58 (45.3) 0.06
1 46 (39.0) 52 (40.6)
2 30 (25.4) 18 (14.1)
Educational status
None/primary 10 (8.5) 4 (3.1) 0.11
Secondary 65 (55.1) 66 (51.6)
Post‑secondary 43 (36.4) 58 (45.3)
Occupation
Housewife/Unemployed/students 21 (17.8) 25 (19.5) 0.43
Business/trading 59 (50.0) 60 (46.9)
Artisan 17 (14.4) 12 (9.4)
Civil servant/salaried worker 21 (17.8) 31 (24.2)
Tribe
Yoruba 109 (9246) 122 (95.3) 0.34
Non‑Yoruba 9 (7.6) 6 (4.7)
Non‑Yoruba ‑ Igbo/Hausa/others








Positive 10 (8.5) 15 (11.7)
Negative 108 (91.5) 113 (88.3)
Clinical malaria
Yes 6 (5.1) 3 (2.3) 0.25*
No 112 (94.9) 125 (97.7)
Repeat episode of malaria
Yes 2 (1.7) 0 (0.0) 0.23*
No 116 (98.3) 128 (100.0)
*Fischer’s exact test
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There was an increase in mean Hb concentration in the PG and 
SP groups at 36 weeks of gestation. In the PG group, about a 
quarter of the participants had Hb concentration <10 g/dl at 
recruitment which reduced to 4.3% at 36 weeks. This finding 
corroborates with results from previous studies on effectiveness 
of PG in reduction of maternal anemia in pregnancy, especially 
when used with hematinic.[14,22-24] The reduction in the 
incidence of maternal anemia is consistent with the findings of 
a previous study that also demonstrated a reduction in anemia 
from 18% at recruitment (24 weeks) to 3% at 36 weeks.[24]
In the SP group, a similar reduction was demonstrated. Less 
than one-fifth of the participants had Hb concentration 
less than 10 g/dl at recruitment which reduced to 4.7% at 
36 weeks gestation. This compares to findings from previous 
studies[5,15,16-18] and further supports the efficacy of SP for IPT 
in prevention of maternal anemia due to malaria infestation 
during pregnancy. The relative increased reduction in anemia 
among participants in the PG group at 36 weeks compared 
to the SP group may be related to the fact that daily use of 
PG enhances compliance to routine antenatal hematinics.
Low birth weight is a known complication of malaria 
infestation during pregnancy. In this study, the mean birth 
weight was similar and comparable between both the study 
groups. The mean birth weight in the SP group was lower 
compared to results from an earlier quoted study,[15] which 
reported mean birth weight of 3.2 kg in a similar group of 
participants. The sample size difference may account for 
this. The finding of this study signifies that PG may have a 
positive effect on infant birth weight at delivery. However, 
several variables have been associated with increased birth 
weight. These include maternal age, maternal/paternal 
anthropometric characteristics, sex of the infant, tribe, 
socioeconomic status, and diet among others.[3] Malaria 
preventive strategies, including drugs and insecticide 
treated nets, have been proven to be beneficial for malaria 
prevention and associated complications in pregnant women. 
The findings from this study agree with earlier studies 
which suggest that PG and SP are effective in reducing the 
incidence of low birth weight following malaria prevention 
during pregnancy.
This study would have been better if the participants in 
the study groups were matched for gestational age, parity, 
environmental living conditions, and educational status. 
However, patient recruitment would have taken longer 
and resources for the research were limited. In monitoring 
compliance to PG, the use of customized charts to mark 
drug (PG) use was not strictly adhered to by most participants. 
The investigator had to rely on empty sachets of used 
drug (PG) and hematinic to assess participants’ compliance 
in the PG group.
This study reiterates the effectiveness of IPT-SP at preventing 
or reducing malaria and associated complications in 
pregnancy with its comparatively low cost and observed 
compliance. PG chemoprophylaxis was also found to be 
effective in combating malaria during pregnancy and as 
such may be a suitable alternative to SP, and can be given in 
selected patients with allergic reactions to sulphonamides.
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